US Stock MarketDetailed Quotes
NBIX Neurocrine Biosciences
- 121.530
- +1.000+0.83%
Close Nov 5 16:00 ET
- 122.460
- +0.930+0.77%
Post 18:10 ET
12.30BMarket Cap32.41P/E (TTM)
122.000High119.080Low748.30KVolume120.010Open120.530Pre Close90.69MTurnover0.75%Turnover Ratio49.20P/E (Static)101.25MShares157.98052wk High4.53P/B12.16BFloat Cap106.85052wk Low--Dividend TTM100.05MShs Float157.980Historical High--Div YieldTTM2.42%Amplitude1.940Historical Low121.188Avg Price1Lot Size
Neurocrine Biosciences Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -25.47%158M | -64.03%64.6M | 204.07%130.3M | 14.88%389.9M | -13.64%123.5M | 114.57%212M | 30.05%179.6M | -209.14%-125.2M | 32.32%339.4M | 3,304.76%143M |
| Net income from continuing operations | 56.20%129.8M | -31.94%65M | 156.66%43.4M | 61.62%249.7M | 65.96%147.7M | 21.31%83.1M | 665.09%95.5M | -651.08%-76.6M | 72.43%154.5M | 1,319.18%89M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --70M | --0 |
| Depreciation and amortization | 18.18%6.5M | 43.14%7.3M | 24.00%6.2M | 36.54%21.3M | 29.55%5.7M | 37.50%5.5M | 30.77%5.1M | 51.52%5M | 43.12%15.6M | 46.67%4.4M |
| Deferred tax | -730.95%-34.9M | 0.48%-41.3M | 50.63%-15.6M | -396.86%-56.7M | 52.59%20.6M | -146.67%-4.2M | -1,238.71%-41.5M | -10,433.33%-31.6M | 344.19%19.1M | 387.23%13.5M |
| Other non cash items | -65.04%-20.3M | 25,050.00%49.9M | 92,200.00%92.1M | -112.50%-200K | 616.67%12.4M | -1,466.67%-12.3M | -110.53%-200K | -108.33%-100K | -88.81%1.6M | 61.90%-2.4M |
| Change In working capital | -90.43%4.4M | -192.40%-86.3M | 45.04%-31.6M | 141.84%28.2M | -3,480.00%-53.7M | 394.87%46M | 267.72%93.4M | 24.04%-57.5M | -503.59%-67.4M | -130.61%-1.5M |
| -Change in receivables | 57.57%-12.9M | -519.05%-17.6M | 72.90%-11.3M | 44.94%-89.3M | 53.98%-21.4M | -36.94%-30.4M | 127.10%4.2M | 46.54%-41.7M | -471.13%-162.2M | -114.29%-46.5M |
| -Change in inventory | -213.79%-3.3M | -431.25%-5.3M | -38.89%1.1M | 307.69%5.4M | -123.08%-900K | 137.66%2.9M | 633.33%1.6M | 20.00%1.8M | -4.00%-2.6M | 178.00%3.9M |
| -Change in payables and accrued expense | -68.33%39.4M | -467.28%-59.5M | -377.61%-18.6M | -43.89%64.3M | -320.74%-83M | 279.27%124.4M | -50.46%16.2M | -41.74%6.7M | 101.76%114.6M | 96.86%37.6M |
| -Change in other working capital | 63.06%-18.8M | -105.46%-3.9M | 88.48%-2.8M | 377.91%47.8M | 1,374.29%51.6M | -175.14%-50.9M | 740.00%71.4M | -127.10%-24.3M | -86.96%-17.2M | -72.00%3.5M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -25.47%158M | -64.03%64.6M | 204.07%130.3M | 14.88%389.9M | -13.64%123.5M | 114.57%212M | 30.05%179.6M | -209.14%-125.2M | 32.32%339.4M | 3,304.76%143M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 125.39%24.7M | 77.60%-28.2M | -30.64%-55M | -163.75%-467.1M | -74.57%-201.8M | -58.73%-97.3M | -500.96%-125.9M | -33.23%-42.1M | -36.02%-177.1M | -587.76%-115.6M |
| Capital expenditure reported | -6.58%-8.1M | -70.59%-11.6M | -31.76%-11.2M | -71.52%-28.3M | -200.00%-5.4M | -547.06%-7.6M | 22.73%-6.8M | -11.84%-8.5M | 29.49%-16.5M | 79.78%-1.8M |
| Net business purchase and sale | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---42.7M | ---- |
| Net investment purchase and sale | 136.57%32.8M | 86.06%-16.6M | -30.36%-43.8M | -272.18%-438.8M | -176.23%-196.4M | -42.38%-89.7M | -396.27%-119.1M | -40.00%-33.6M | -10.39%-117.9M | -318.10%-71.1M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 125.39%24.7M | 77.60%-28.2M | -30.64%-55M | -163.75%-467.1M | -74.57%-201.8M | -58.73%-97.3M | -500.96%-125.9M | -33.23%-42.1M | -36.02%-177.1M | -587.76%-115.6M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 40.43%26.4M | -10,203.45%-293M | 752.44%69.9M | 127.87%65.3M | 43.90%35.4M | 64.91%18.8M | 101.05%2.9M | 34.43%8.2M | -955.11%-234.3M | 1,266.67%24.6M |
| Net issuance payments of debt | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- | -278,900.00%-279M | --0 |
| Proceeds from stock option exercised by employees | 40.43%26.4M | 444.83%15.8M | 752.44%69.9M | 46.09%65.3M | 43.90%35.4M | 64.91%18.8M | 11.54%2.9M | 34.43%8.2M | 62.55%44.7M | 1,266.67%24.6M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 40.43%26.4M | -10,203.45%-293M | 752.44%69.9M | 127.87%65.3M | 43.90%35.4M | 64.91%18.8M | 101.05%2.9M | 34.43%8.2M | -955.11%-234.3M | 1,266.67%24.6M |
| Net cash flow | ||||||||||
| Beginning cash position | -12.19%147.7M | 262.28%404.3M | -4.29%259.1M | -21.31%270.7M | 37.14%301.7M | -1.69%168.2M | -59.86%111.6M | -21.31%270.7M | 80.77%344M | -30.00%220M |
| Current changes in cash | 56.63%209.1M | -553.36%-256.6M | 191.26%145.2M | 83.47%-11.9M | -182.50%-42.9M | 173.01%133.5M | 152.95%56.6M | -141.06%-159.1M | -146.84%-72M | 75.08%52M |
| Effect of exchange rate changes | ---- | ---- | ---- | 123.08%300K | --300K | ---- | ---- | ---- | ---1.3M | ---- |
| End cash Position | 18.36%357.1M | -12.19%147.7M | 262.28%404.3M | -4.29%259.1M | -4.29%259.1M | 37.14%301.7M | -1.69%168.2M | -59.86%111.6M | -21.31%270.7M | -21.31%270.7M |
| Free cash flow | -26.66%149.9M | -69.33%53M | 189.08%119.1M | 11.99%361.6M | -16.36%118.1M | 103.38%204.4M | 33.64%172.8M | -177.96%-133.7M | 38.52%322.9M | 3,104.26%141.2M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data